Advanced and metastatic non-small cell lung cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

The most advanced stage of the disease is known as advanced non-small cell lung cancer (NSCLC), also referred to as metastatic lung cancer. It describes any size or type of non-small cell lung cancer (adenocarcinoma, squamous cell carcinoma, large cell carcinoma) that has metastasized-that is, spread-from one lung to another, to another part of the body, or within or near the lungs. Lung cancer now ranks first among all cancers in terms of cancer-related deaths worldwide, with North America and Europe having the highest incidence of the disease. Patients with non-small cell lung cancer (NSCLC) in stages I to IIIA typically opt for surgery. Additionally, patients who have had their lung cancer removed are at risk of recurrence and so receive adjuvant chemotherapy. In most cases, patients with stage IIIB and stage IV non-small cell lung cancer (NSCLC) receive chemotherapy rather than surgery because surgery is the treatment of choice for those with stage I to stage IIIA NSCLC.

Description

Advanced non-small cell lung cancer (NSCLC), also referred to as metastatic lung cancer is the most severe stage of lung cancer. It describes any size or type of non-small cell lung cancer (adenocarcinoma, squamous cell carcinoma, large cell carcinoma) that has metastasized-that is, spread-from one lung to another, to another part of the body, or within or near the lungs. Though incurable, stage 4 NSCLC is still treatable. A little more than 85% of lung cancers are non-small cell lung cancers (NSCLC). Histologically, NSCLC is separated into adenocarcinoma, squamous cell carcinoma (SCC), and large cell carcinoma. Each year, advanced NSCLC is diagnosed in more than one million people worldwide. In the first-line metastatic setting, immunotherapy and targeted therapies have improved outcomes; however, the majority of patients eventually experience disease progression and require chemotherapy. Despite its limited effectiveness and well-known side effects, chemotherapy has long been the only option left for patients with advanced NSCLC when other treatments have failed to work.

Advanced and metastatic non-small cell lung cancer (Epidemiology)

With the highest incidence in developed nations like North America and Europe, lung cancer is currently the most common type of cancer that results in cancer-related death worldwide. The incidence of lung cancer varies widely among various geographical areas. The highest incidence is found in Polynesia (37.3 per 100,000 people per year). The lowest infection rate is in West Africa, where it is 2.2 per 100,000 people per year. The incidence is anticipated to rise in the upcoming years as a result of the rise in smoking in developing nations, particularly China and India. Global lung cancer trends generally lag behind smoking by decades. In many nations, including the US, Canada, the UK, and Australia, smoking rates have decreased as a result. But even though lung cancer rates are starting to level off in the United States, they are still rising globally among women. Despite having very low smoking rates, Chinese women are more likely than European women to develop lung cancer. People between the ages of 50 and 70 are most commonly affected by lung cancer. Lung cancer is very unlikely to develop in either men or women over the age of 39. Following that, it gradually started to rise, peaking among people over the age of 70. Men of all ages continue to have a higher risk of developing lung cancer after the age of 40. In general, men are more likely than women to develop lung cancer. In the United States and northern and western Europe, the incidence of lung cancer in men has decreased. Lung cancer cases are rising quickly in Eastern and Southern European nations. The majority of Western nations are dealing with the worrying trend of rising incidence among female patients and younger patients. Women are typically younger when symptoms first appear and are more likely to present with localized disease and adenocarcinoma. All racial and ethnic groups have seen a decrease in the overall incidence of lung cancer among men and women aged 30 to 54 over the past 20 years. The incidence in men has, however, sharply decreased. Lung cancer is more common in young women than in young men, for this reason. For instance, the female-to-male ratio for lung cancer among non-Hispanic whites and Hispanics aged 44 to 49 years increased from 0.88 in 1995-1999 to 1.17 in 2010-2014. year. This reversal can be partly attributed to women born after 1965 smoking more often. However, despite the fact that there were fewer differences between smokers in this age group, women did not generally smoke more than men, suggesting that other factors may be at play. Women, for instance, may be more susceptible to the cancer-causing effects of smoking. While lung cancer rates for white women and African-American women are comparable, African-American men have a roughly 45% higher risk than white men. Differences in smoking habits were the cause of this increased incidence. On the other hand, recent data point to slight sensitivity variations. African Americans had a 13% lower 5-year survival rate than whites between 1995 and 2001. For both men and women, this racial disparity persisted throughout the diagnosis process. An analysis of trends in lung cancer 5-year survival from 1975 to 2003 revealed that while white 5-year survival rates slightly increased, African-American survival rates remained stable. White people currently have a 5-year survival rate of 16%, while non-white people have a survival rate of 13%.

Advanced and metastatic non-small cell lung cancer -Current Market Size & Forecast Trends

The market for advanced and metastatic non-small cell lung cancer (NSCLC) is projected to grow significantly, with estimates indicating a value of approximately USD 19.10 billion in 2023. Growth is driven by increasing approvals of targeted therapies (e.g., EGFR and ALK inhibitors) and immunotherapies like PD-1/PD-L1 inhibitors. The market is projected to grow at a CAGR of ~9% by 2035, fueled by rising incidence rates and a shift toward personalized medicine.

Patients with non-small cell lung cancer (NSCLC) stage I to IIIA have surgery as their first option. While chemotherapy is typically given to people with stage IIIB and stage IV NSCLC. Adjuvant chemotherapy is given to patients who have had their lung cancer removed because they are at risk of recurrence. Advanced non-small cell lung cancer is being treated with a growing emphasis on molecularly guided therapy. Interest in the preoperative management of early-stage resectable NSCLC has increased as a result of the success of molecularly guided treatment of advanced NSCLC. Nivolumab, a novel immune checkpoint inhibitor, was approved by the US Food and Drug Administration (FDA) in March 2022 for use in patients with resectable NSCLC (tumors smaller than 4 cm or node-positive). The approval was based on the findings of the CheckMate 816 study, which included people with stage IB, II, or IIIA NSCLC. There are still studies being done on other biologics for neoadjuvant therapy. For patients who cannot undergo surgery, radiation therapy is a viable treatment option. The provision of appropriate palliative care is a crucial component of treatment because the majority of non-small cell lung cancers cannot be treated with currently available therapies. A growing body of research supports the delivery of standard oncology care along with palliative care when advanced NSCLC is initially diagnosed The treatment of advanced and metastatic non-small cell lung cancer (NSCLC) has become an exciting but increasingly challenging task due to breakthrough events and continuous advances. This is especially true for the NSCLC subgroup with tumor motor modifications. Despite the fact that tyrosine kinase inhibitors (TKIs) are well established for the treatment of anaplastic lymphoma (ALK) and epidermal growth factor receptor (EGFR), new targets have been discovered and new TKIs have recently entered clinical use. Even for KRAS mutations that were previously regarded as "off-target" changes, promising new medications are emerging. The further development of new therapeutic approaches has been facilitated by the identification of resistance mechanisms and thorough molecular analysis.

Report Highlights

Advanced and metastatic non-small cell lung cancer - Current Market Trends

Advanced and metastatic non-small cell lung cancer - Current & Forecasted Cases across the G8 Countries

Advanced and metastatic non-small cell lung cancer - Market Opportunities and Sales Potential for Agents

Advanced and metastatic non-small cell lung cancer - Patient-based Market Forecast to 2035

Advanced and metastatic non-small cell lung cancer - Untapped Business Opportunities

Advanced and metastatic non-small cell lung cancer - Product Positioning Vis-a-vis Competitors' Products

Advanced and metastatic non-small cell lung cancer - KOLs Insight